Formycon AG Stock

Price

Target price

/ Tradegate WKN: A1EWVY / Name: Formycon / Stock / Biotechnology & Medical Research / Small Cap /

Please give a prediction to see the opinions of the community

sharewise uses Wisdom of crowds to gather information regarding a security. Wisdom of crowds works best if you do not see the predictions of others before giving your estimate. Please click one button to see how the community sees this security.

JS chart by amCharts

From: to:

Zoom:

Your prediction

Formycon AG Stock

A loss of -2.840% shows a downward development for Formycon AG.

Based on 2 Buy predictions and 1 Sell predictions the sentiment towards Formycon AG is rather balanced.

With a target price of 100 € there is potential for a 266.97% increase which would mean more than doubling the current price of 27.25 € for Formycon AG.

Our community identified positive and negative aspects for Formycon AG stock for the coming years. 4 users see the criterium "Worthwhile Investment for the next years" as a plus for the Formycon AG stock. On the other hand our users think that "Valuation (undervalued/overvalued)" could be a problem in the future.

What does Formycon do?

Pros and Cons of Formycon AG in the next few years

Pros

C******** o* t** e**********

S********** s********

B****

Cons

W********* I********* f** t** n*** y****

G***** c******* t* c**********

M***** P*******

Tell us your opinion to access the 'Wisdom of the Crowds'

Your Opinion

Legal notice

Performance of Formycon AG vs. its peers

Security	Change(%)	1w	1m	1y	YTD	3y	5y
Formycon AG
MagForce AG
B.R.A.I.N. Biotechnology Research and Information Network AG
Ardelyx Inc.

sharewise BeanCounterBot

The analysis provided is generated by an artificial intelligence system and is provided for informational purposes only. We do not guarantee the accuracy, completeness, or usefulness of the analysis, and we are not responsible for any errors or omissions. Use of the analysis is at your own risk.

Last updated at 2023-04-15

Upon initial analysis of Formycon's financial statements, it's evident that this biotechnology and medical research company has seen substantial fluctuations in its financial position over the years. While it may have experienced a few challenges, there are also some notable strengths present in the company's financials. This report aims to provide an in-depth analysis, highlighting both the pros and cons to help potential investors make an informed decision based on Formycon's financial health.

Growing Total Assets: From 2019 to 2021, Formycon has experienced significant growth in its total assets, going from €53,555,323.89 to €66,333,000.00. This uptick is a positive sign, indicating that the company's financial position is improving, and there is potential value generated from its operations.

Reduced Liabilities: The total liabilities of Formycon have shown a decreasing trend, moving from €5,344,603.40 in 2019 to €4,269,670.00 in 2021. A decrease in liabilities is an encouraging sign, suggesting that the company is managing its debt levels effectively.

Feedback